Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Trypanosoma cruzi | proteasome subunit beta type-5, putative | 0.0335 | 0.5 | 0.5 |
Echinococcus multilocularis | proteasome (prosome, macropain) | 0.0335 | 0.5 | 0.5 |
Entamoeba histolytica | proteasome subunit beta type 5 precursor, putative | 0.0335 | 0.5 | 0.5 |
Schistosoma mansoni | proteasome catalytic subunit 3 (T01 family) | 0.0335 | 0.5 | 0.5 |
Mycobacterium ulcerans | proteasome PrcB | 0.0335 | 0.5 | 0.5 |
Leishmania major | proteasome beta 5 subunit, putative | 0.0335 | 0.5 | 0.5 |
Loa Loa (eye worm) | proteasome A-type and B-type family protein | 0.0335 | 0.5 | 0.5 |
Mycobacterium tuberculosis | Proteasome beta subunit PrcB; assembles with alpha subunit PrcA. | 0.0335 | 0.5 | 0.5 |
Trichomonas vaginalis | Family T1, proteasome beta subunit, threonine peptidase | 0.0335 | 0.5 | 0.5 |
Trypanosoma cruzi | proteasome subunit beta type-5, putative | 0.0335 | 0.5 | 0.5 |
Echinococcus granulosus | proteasome prosome macropain | 0.0335 | 0.5 | 0.5 |
Trypanosoma brucei | proteasome subunit beta type-5, putative | 0.0335 | 0.5 | 0.5 |
Giardia lamblia | Proteasome subunit beta type 5 precursor | 0.0335 | 0.5 | 0.5 |
Plasmodium vivax | proteasome subunit beta type-5, putative | 0.0335 | 0.5 | 0.5 |
Mycobacterium leprae | proteasome (beta subunit) PrcB | 0.0335 | 0.5 | 0.5 |
Toxoplasma gondii | proteasome subunit beta type, putative | 0.0335 | 0.5 | 0.5 |
Plasmodium falciparum | proteasome subunit beta type-5 | 0.0335 | 0.5 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
MIC (functional) | = 0 ug ml-1 | Minimum inhibitory concentration to prevent all movement of cysts and evaginated scoleces of in vitro Taenia crassiceps screen after 48 h; | ChEMBL. | 2769679 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.